Nektar and Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15 Receptor Agonist, in combination with CAR Cell Therapies at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® ...Middle East

SAN FRANCISCO, April 23, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced that collaborators from the Cairo Laboratory at New York Medical College today presented data from several preclinical studies demonstrating the potential of NKTR-255 to enhance the anti-tumor...

Hence then, the article about nektar and collaborators present preclinical data on nktr 255 a novel il 15 receptor agonist in combination with car cell therapies at the 2022 tandem meetings transplantation cellular therapy meetings of astct and cibmtr was published today ( Sunday 24/04/2022 - 12:49 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Nektar and Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15 Receptor Agonist, in combination with CAR Cell Therapies at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® )

Also on site :

• Travel Warning Issued For Millions Across US
• ‘Change is inevitable’: What is next for Iran?
• Australian Open: Sinner overcomes cramps; Keys, Pegula advance; Osaka withdraws